Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study

Importance: Checkpoint inhibitor pneumonitis (CIP) is a rare but serious adverse event that may impact treatment decisions. However, there is limited information comparing CIP risks between immune checkpoint inhibitor (ICI) monotherapy and combination with chemotherapy due to a lack of direct cross-...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huixia, Zheng, Yifan, Xu, Peihang, Li, Zimu, Kuang, Yukun, Feng, Xiaoqing, He, Junhao, Li, Jia, Chen, Xiao, Bai, Lihong, Tang, Ke-Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133569/
https://www.ncbi.nlm.nih.gov/pubmed/37124234
http://dx.doi.org/10.3389/fphar.2023.1142016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133569/
https://www.ncbi.nlm.nih.gov/pubmed/37124234
http://dx.doi.org/10.3389/fphar.2023.1142016

Ejemplares similares